The Gene Therapy Market size was valued at USD 8.65 Billion in 2023 and the total Gene Therapy market revenue is expected to grow at a CAGR of 16% from 2024 to 2030, reaching nearly USD 24.45 Billion by 2030.Gene Therapy Market Overview
Gene therapy is a medical technique that aims to cure or stop disease by fixing the genetic makeup and genetic issue beneath the surface. Gene therapy methods enable physicians to address a medical condition by changing an individual's genetic composition rather than resorting to medications or operations. The First method of gene therapy, often called gene transfer or gene addition, was developed to:• Introduce a new gene into cells to help fight a disease.
• Introduce a non-faulty copy of a gene to stand in for the altered copy causing Disease.
The worldwide gene therapy market is quickly enlarging and is expected to experience substantial growth in the future. The gene therapy market aims to offer treatment for genetic disorders which are currently incurable. For ex: (Huntington's disease, Sickle Cell Disease) The gene therapy industry is dedicated to creating novel treatments that target the underlying cause of these illnesses. The rising incidence of genetic disorders is the main driving force behind the growth of the gene therapy market. The rising occurrence of genetic disorders worldwide is causing a higher need for gene therapy. Developing gene therapies is a costly and intricate process, leading to high expenses for patients. For ex: (Voretigene neparvovec-rzyl injection is indicated for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy with viable retinal cells. Costs $850 000 for one time treatment). The success of gene therapies relies heavily on the delivery mechanism, must translocate the healthy gene to specific cells within the body. Moreover, the immune system identify the gene therapy as an external threat, triggering an immune reaction that diminishes the therapy's efficacy. The pharmaceutical companies have a great opportunity to create groundbreaking therapies in the gene therapy market.• As per the report published by Alliance for Regenerative Medicine, there are more than 1400 companies globally focusing on CGT (Cell Gene Therapy) and over 3500 therapies in preclinical and clinical development.
To know about the Research Methodology :- Request Free Sample Report
Gene Therapy Market Dynamics
Increase In The Demand For Gene Therapy Interventions Drives The Gene Therapy Market The increase in genetic conditions like cystic fibrosis, sickle cell anemia, and muscular dystrophy increase the demand for gene therapy interventions. The increasing occurrence highlights the need for creative treatment methods. Gene therapy provides possible solutions by focusing on the underlying causes of these disorders, offering a hopeful path for meeting medical needs in affected group. Innovations like hemophilia gene therapy and CRISPR-Cas9 have transformed the field of gene editing by enhancing accuracy, effectiveness, and cost-effectiveness. This advancement drives expansion in the gene therapy industry by enabling precise genetic alterations for treating diseases. These developments result in better treatments, prompting investments and leading to the development of creative gene therapy options for various medical issues. High Expenses Associated With Gene Therapy Limits The Growth of Gene Therapy Market Immune reactions to viral vectors or foreign gene products hamper the effectiveness of gene therapy and lead to negative outcomes. Approaches to deal with the obstacle involve immunomodulatory treatments and modified vectors created to avoid detection by the immune system. It is essential to conquer these reactions to guarantee the safety and efficacy of gene therapy treatments. The high expenses associated with gene therapy come from complex manufacturing processes, thorough clinical trials, and strict regulatory requirements. The financial obstacles companies face restrict their ability to invest and impede their ability to innovate and enter new markets. It is crucial to find ways to lower the expensive costs of gene therapy to advance the field and make it more accessible to a larger number of patient market report includes information on recent developments, trade regulations, import-export analysis, production analysis, optimizing the value chain, market share, impact of domestic and localized market players, opportunities for emerging revenue pockets, changes in market regulations, strategic analysis for market growth, market size, category market growth, application niches and dominance, product approvals, product launches, geographic expansions, and technological innovations in the market. Increase In Personalized Treatment Creates Opportunities In The Gene Therapy Market Gene therapy enables personalized treatment by focusing on genetic mutations and providing customized solutions for each patient. Focusing on each individual's specific genetic characteristics drives the growth of the market by offering personalized and highly efficient treatments, ultimately transforming the field of medical care. Organizations are more and more creating strategic alliances to create gene therapy products for identifying genetic disorders. Collaborations make it easier to create new technologies and platforms for detecting diseases. Extended contracts allow businesses to provide flexible pricing for gene therapy products, meeting the needs and demand of customers. These collaborations open up chances for both parties to grow and benefit in the market. Gene therapy provides customized treatment possibilities that are individualized for each patient according to their genetic composition. With the increasing demand for personalized medicine, it anticipated that the gene therapy market see significant growth. Maintaining The Accuracy For Delivering The Therapeutic Gene To Target Cells Efficiently One of the biggest challenges is delivering the therapeutic gene to the target cells efficiently. Different delivery methods, such as viral vectors and non-viral vectors, each have their own limitations including immunogenicity, toxicity, and difficulty in targeting specific tissues or cells. The body's immune system recognizes the vectors used in gene therapy as foreign invaders, leading to immune responses that neutralize the therapy or cause adverse reactions in patients. These immune responses limits the effectiveness of repeated dosing. And It indicates that the safety of gene therapy is very crucial. Viral vectors, in particular, carries the risks such as Insertional mutagenesis, it is a condition where the introduced gene disrupts the function of an existing gene, potentially leading to cancer or other adverse effects. There is a risk of unintended gene expression or disruption of normal gene function, leading to unforeseen side effects. Ensuring that the therapeutic gene integrates into the genome at the intended site and does not interfere the function of other genes is a significant challenge. Gene therapy involves novel technologies and poses unique regulatory challenges. Regulatory agencies needs to balance the need for safety and efficacy with the urgency of bringing potentially life-saving treatments to patients.Gene Therapy Market Segment Analysis
Based on Type, Viral vectors are developed from viruses that have been altered to translocate therapeutic genes to specific cells. Popular types of viral vectors are retroviruses, adenoviruses, adeno-associated viruses (AAVs), and lentiviruses. Viral vectors are currently the most popular in the gene therapy industry because of their strong ability to efficiently transfer genes to both dividing and non-dividing cells. AAVs (adeno-associated viruses) have become increasingly popular because of their excellent safety record and ability to provide lasting gene expression. Despite their benefits, viral vectors trigger immune reactions, have restricted cargo space, and present dangers like insertional mutagenesis.Non-viral vectors are different delivery systems that do not use viral components. These vectors could consist of DNA without packaging, liposomes, nanoparticles, and polymer-based delivery methods. Non-viral vectors are becoming more popular in the gene therapy industry due to their ability to reduce immune responses, be easily scaled, and accommodate various cargo sizes. Nevertheless, they frequently demonstrate reduced transduction effectiveness when contrasted with viral vectors. Non-viral vectors encounter difficulties in achieving effective gene delivery, including obstacles like degradation by nucleases and restricted cellular uptake.
Gene Therapy Market Regional Insights
North America, especially the United States, leads the gene therapy market Thanks to its strong research infrastructure, supportive regulations, and significant investments in biotech and pharmaceutical sectors. Regulatory approval is given to gene therapy products, are now more commonly used in clinical practice for treating genetic disorders, cancer, and rare diseases. Institutions and companies in North America lead the way in gene therapy research, spearheading advancements in vector development, gene editing technologies, and clinical trial design. Organizations like the FDA are essential for monitoring the progression and authorization of gene therapy products to uphold safety, effectiveness, and quality criteria. Europe Countries like the UK, Germany, and France are at the forefront of research and clinical development in gene therapy, making Europe a crucial market for the technology. Regulatory approval is granted in Europe for gene therapy products, are now being more commonly used in healthcare systems, especially for treating rare diseases and specific types of cancer. European academic institutions, biotech companies, and pharmaceutical firms are engaged in gene therapy research, working together on clinical trials and investigating innovative therapeutic methods. The European Medicines Agency (EMA) monitors gene therapy products in the European Union to ensure they meet strict regulatory standards for safety, effectiveness, and quality.Gene Therapy Market Competitive Landscapes
• In December 2023, Libmeldy received approval from the Swiss Agency for Therapeutic Products to treat early-onset metachromatic leukodystrophy, marking a significant advancement in addressing the rare disorder's therapeutic needs.
• In May 2023, Krystal Biotech's VYJUVEK gene therapy gained approval for treating Dystrophic Epidermolysis Bullosa, offering hope to patients with the debilitating condition.
• In January 2023, Voyager Therapeutics and Neurocrine Biosciences initiated a strategic collaboration to commercialize and develop Voyager's GBA1 program and other innovative gene therapies targeting neurological disorders, promising advancements in the critical field of medicine.
Gene Therapy Industry Ecosystem
Gene Therapy Market Scope: Inquiry Before Buying
Gene Therapy Market Report Coverage Details Base Year: 2023 Forecast Period: 2024-2030 Historical Data: 2018 to 2023 Market Size in 2023: USD 8.65 Billion Forecast Period 2024 to 2030 CAGR: 16% Market Size in 2030: USD 24.45 Billion Segments Covered: by Delivery Method In Vivo Ex Vivo by Vector Type Viral Vectors Non-Viral Vectors by Therapeutic Area Oncology Neurological Disorders Cardiovascular Diseases Others by Route of Administration Intravenous Others by End User Hospitals and Clinics Academic and Research Institutes Biotechnology and Pharmaceutical Companies Others Gene Therapy Market by Region
North America (United States, Canada, and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, and the Rest of Europe) Asia Pacific (China, South Korea, Japan, India, Indonesia, Malaysia, Australia, Vietnam, Taiwan, Bangladesh, Pakistan, and the Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria, and the Rest of ME&A) South America (Brazil, Argentina Rest of South America)Gene Therapy Market Key Players
1. Organogenesis 2. JCR Pharmaceuticals 3. Japan Tissue Engineering 4. AVITA Medical 5. CHIESI Farmaceutici 6. Stempeutics Research 7. Biosolution 8. MolMed 9. APAC Biotech 10. Gilead Sciences 11. Medipost 12. JW CreaGene 13. Vericel 14. Takeda Pharmaceutical Company 15. Novartis AG 16. Osiris Therapeutics 17. AnGes 18. Tego Sciences 19. Dendreon 20. CollPlantFrequently Asked Questions:
1] What segments are covered in Global Gene Therapy Market report? Ans. The segments covered in Global Gene Therapy Market report are based on method, Vector Type and End User. 2] Which region is expected to hold the highest share in the Global Gene Therapy Market? Ans. North America is expected to hold the highest share in the Global Gene Therapy Market. 3] Who are the top key players in the Global Gene Therapy Market? Ans. CHIESI Farmaceutici, Stempeutics Research, Biosolution, APAC Biotech, Gilead Sciences, Medipost, JW CreaGene, Vericel, Takeda Pharmaceutical Company are the key players in Gene Therapy Market. 4] Which segment holds the largest market share in the Global Gene Therapy market by 2030? Ans. Spinal Muscular Atrophy (SMA) Indication segment will hold the largest market share in the Global Gene Therapy market by 2030. 5] What is the market size of the Global Gene Therapy market by 2030? Ans. The market size of the Global Gene Therapy market is USD 24.45 Bn. by 2030. 6] What was the market size of the Global Gene Therapy market in 2022? Ans. The market size of the Global Gene Therapy market was worth USD 8.65 Bn. in 2023.
1. Gene Therapy Market Introduction 1.1. Study Assumption and Market Definition 1.2. Scope of the Study 1.3. Evolution of Gene Therapy 1.4. Executive Summary 2. Global Gene Therapy Market: Competitive Landscape 2.1. MMR Competition Matrix 2.2. Competitive Landscape 2.3. Market share analysis of major players 2.4. Delivery Therapeutic Area-specific analysis 2.5. Key Players Benchmarking 2.5.1. Company Name 2.5.2. Delivery Therapeutic Area Segment 2.5.3. Route of Administration Segment 2.5.4. Revenue (2023) 2.5.5. Geographic distribution of major customers 2.6. Market Structure 2.6.1. Market Leaders 2.6.2. Market Followers 2.6.3. Emerging Players 2.7. Mergers and Acquisitions Details 3. Gene Therapy Market: Dynamics 3.1. Gene Therapy Market Trends 3.2. Gene Therapy Market Dynamics 3.2.1.1. Gene Therapy Market Drivers 3.2.1.2. Gene Therapy Market Restraints 3.2.1.3. Gene Therapy Market Opportunities 3.2.1.4. Gene Therapy Market Challenges 3.3. PORTER’s Five Forces Analysis 3.4. PESTLE Analysis 3.5. Regulatory Landscape by Region 3.5.1. North America 3.5.2. Europe 3.5.3. Asia Pacific 3.5.4. South America 3.6. Analysis of Government Schemes and Initiatives For the Gene Therapy Industry 3.7. Technological Advancements 4. Gene Therapy Market: Global Market Size and Forecast by Segmentation (by Value USD Mn) (2023-2030) 4.1. Gene Therapy Market Size and Forecast, by Delivery Therapeutic Area (2023-2030) 4.1.1. In Vivo 4.1.2. Ex Vivo 4.2. Gene Therapy Market Size and Forecast, by Vector Type (2023-2030) 4.2.1. Viral Vectors 4.2.2. Non-Viral Vectors 4.3. Gene Therapy Market Size and Forecast, by Therapeutic Area (2023-2030) 4.3.1. Column-based Isolation and Purification 4.3.2. Magnetic Bead-based Isolation and Purification 4.3.3. Reagent-based Isolation and Purification 4.3.4. Others 4.4. Gene Therapy Market Size and Forecast, by Route of Administration (2023-2030) 4.4.1. Intravenous 4.4.2. Others 4.5. Gene Therapy Market Size and Forecast, by End User (2023-2030) 4.5.1. Hospitals and Clinics 4.5.2. Academic and Research Institutes 4.5.3. Biotechnology and Pharmaceutical Companies 4.5.4. Others 4.6. Gene Therapy Market Size and Forecast, by Region (2023-2030) 4.6.1. North America 4.6.2. Europe 4.6.3. Asia Pacific 4.6.4. Middle East and Africa 4.6.5. South America 5. North America Gene Therapy Market Size and Forecast by Segmentation (by Value USD Mn) (2023-2030) 5.1. North America Gene Therapy Market Size and Forecast, by Delivery Therapeutic Area (2023-2030) 5.1.1. In Vivo 5.1.2. Ex Vivo 5.2. North America Gene Therapy Market Size and Forecast, by Vector Type (2023-2030) 5.2.1. Viral Vectors 5.2.2. Non-Viral Vectors 5.3. North America Gene Therapy Market Size and Forecast, by Therapeutic Area (2023-2030) 5.3.1. Oncology 5.3.2. Neurological Disorders 5.3.3. Cardiovascular Diseases 5.3.4. Others 5.4. North America Gene Therapy Market Size and Forecast, by Route of Administration (2023-2030) 5.4.1. Intravenous 5.4.2. Others 5.5. North America Gene Therapy Market Size and Forecast, by End User (2023-2030) 5.5.1. Hospitals and Clinics 5.5.2. Academic and Research Institutes 5.5.3. Biotechnology and Pharmaceutical Companies 5.5.4. Others 5.6. North America Gene Therapy Market Size and Forecast, by Country (2023-2030) 5.6.1. United States 5.6.1.1. United States Gene Therapy Market Size and Forecast, by Delivery Therapeutic Area (2023-2030) 5.6.1.1.1. In Vivo 5.6.1.1.2. Ex Vivo 5.6.1.2. United States Gene Therapy Market Size and Forecast, by Vector Type (2023-2030) 5.6.1.2.1. Viral Vectors 5.6.1.2.2. Non-Viral Vectors 5.6.1.3. United States Gene Therapy Market Size and Forecast, by Therapeutic Area (2023-2030) 5.6.1.3.1. Oncology 5.6.1.3.2. Neurological Disorders 5.6.1.3.3. Cardiovascular Diseases 5.6.1.3.4. Others 5.6.1.4. United States Gene Therapy Market Size and Forecast, by Route of Administration (2023-2030) 5.6.1.4.1. Intravenous 5.6.1.4.2. Others 5.6.1.5. United States Gene Therapy Market Size and Forecast, by End User (2023-2030) 5.6.1.5.1. Hospitals and Clinics 5.6.1.5.2. Academic and Research Institutes 5.6.1.5.3. Biotechnology and Pharmaceutical Companies 5.6.1.5.4. Others 5.6.2. Canada 5.6.2.1. Canada Gene Therapy Market Size and Forecast, by Delivery Therapeutic Area (2023-2030) 5.6.2.1.1. In Vivo 5.6.2.1.2. Ex Vivo 5.6.2.2. Canada Gene Therapy Market Size and Forecast, by Vector Type (2023-2030) 5.6.2.2.1. Viral Vectors 5.6.2.2.2. Non-Viral Vectors 5.6.2.3. Canada Gene Therapy Market Size and Forecast, by Therapeutic Area (2023-2030) 5.6.2.3.1. Oncology 5.6.2.3.2. Neurological Disorders 5.6.2.3.3. Cardiovascular Diseases 5.6.2.3.4. Others 5.6.2.4. Canada Gene Therapy Market Size and Forecast, by Route of Administration (2023-2030) 5.6.2.4.1. Intravenous 5.6.2.4.2. Others 5.6.2.5. Canada Gene Therapy Market Size and Forecast, by End User (2023-2030) 5.6.2.5.1. Hospitals and Clinics 5.6.2.5.2. Academic and Research Institutes 5.6.2.5.3. Biotechnology and Pharmaceutical Companies 5.6.2.5.4. Others 5.6.3. Mexico 5.6.3.1. Mexico Gene Therapy Market Size and Forecast, by Delivery Therapeutic Area (2023-2030) 5.6.3.1.1. In Vivo 5.6.3.1.2. Ex Vivo 5.6.3.2. Mexico Gene Therapy Market Size and Forecast, by Vector Type (2023-2030) 5.6.3.2.1. Viral Vectors 5.6.3.2.2. Non-Viral Vectors 5.6.3.3. Mexico Gene Therapy Market Size and Forecast, by Therapeutic Area (2023-2030) 5.6.3.3.1. Oncology 5.6.3.3.2. Neurological Disorders 5.6.3.3.3. Cardiovascular Diseases 5.6.3.3.4. Others 5.6.3.4. Mexico Gene Therapy Market Size and Forecast, by Route of Administration (2023-2030) 5.6.3.4.1. Intravenous 5.6.3.4.2. Others 5.6.3.5. Mexico Gene Therapy Market Size and Forecast, by End User (2023-2030) 5.6.3.5.1. Hospitals and Clinics 5.6.3.5.2. Academic and Research Institutes 5.6.3.5.3. Biotechnology and Pharmaceutical Companies 5.6.3.5.4. Others 6. Europe Gene Therapy Market Size and Forecast by Segmentation (by Value USD Mn) (2023-2030) 6.1. Europe Gene Therapy Market Size and Forecast, by Delivery Therapeutic Area (2023-2030) 6.2. Europe Gene Therapy Market Size and Forecast, by Vector Type (2023-2030) 6.3. Europe Gene Therapy Market Size and Forecast, by Therapeutic Area (2023-2030) 6.4. Europe Gene Therapy Market Size and Forecast, by Route of Administration (2023-2030) 6.5. Europe Gene Therapy Market Size and Forecast, by End User (2023-2030) 6.6. Europe Gene Therapy Market Size and Forecast, by Country (2023-2030) 6.6.1. United Kingdom 6.6.1.1. United Kingdom Gene Therapy Market Size and Forecast, by Delivery Therapeutic Area (2023-2030) 6.6.1.2. United Kingdom Gene Therapy Market Size and Forecast, by Vector Type (2023-2030) 6.6.1.3. United Kingdom Gene Therapy Market Size and Forecast, by Therapeutic Area (2023-2030) 6.6.1.4. United Kingdom Gene Therapy Market Size and Forecast, by Route of Administration (2023-2030) 6.6.1.5. United Kingdom Gene Therapy Market Size and Forecast, by End User (2023-2030) 6.6.2. France 6.6.2.1. France Gene Therapy Market Size and Forecast, by Delivery Therapeutic Area (2023-2030) 6.6.2.2. France Gene Therapy Market Size and Forecast, by Vector Type (2023-2030) 6.6.2.3. France Gene Therapy Market Size and Forecast, by Therapeutic Area (2023-2030) 6.6.2.4. France Gene Therapy Market Size and Forecast, by Route of Administration (2023-2030) 6.6.2.5. France Gene Therapy Market Size and Forecast, by End User (2023-2030) 6.6.3. Germany 6.6.3.1. Germany Gene Therapy Market Size and Forecast, by Delivery Therapeutic Area (2023-2030) 6.6.3.2. Germany Gene Therapy Market Size and Forecast, by Vector Type (2023-2030) 6.6.3.3. Germany Gene Therapy Market Size and Forecast, by Therapeutic Area (2023-2030) 6.6.3.4. Germany Gene Therapy Market Size and Forecast, by Route of Administration (2023-2030) 6.6.3.5. Germany Gene Therapy Market Size and Forecast, by End User (2023-2030) 6.6.4. Italy 6.6.4.1. Italy Gene Therapy Market Size and Forecast, by Delivery Therapeutic Area (2023-2030) 6.6.4.2. Italy Gene Therapy Market Size and Forecast, by Vector Type (2023-2030) 6.6.4.3. Italy Gene Therapy Market Size and Forecast, by Therapeutic Area (2023-2030) 6.6.4.4. Italy Gene Therapy Market Size and Forecast, by Route of Administration (2023-2030) 6.6.4.5. Italy Gene Therapy Market Size and Forecast, by End User (2023-2030) 6.6.5. Spain 6.6.5.1. Spain Gene Therapy Market Size and Forecast, by Delivery Therapeutic Area (2023-2030) 6.6.5.2. Spain Gene Therapy Market Size and Forecast, by Vector Type (2023-2030) 6.6.5.3. Spain Gene Therapy Market Size and Forecast, by Therapeutic Area (2023-2030) 6.6.5.4. Spain Gene Therapy Market Size and Forecast, by Route of Administration (2023-2030) 6.6.5.5. Spain Gene Therapy Market Size and Forecast, by End User (2023-2030) 6.6.6. Sweden 6.6.6.1. Sweden Gene Therapy Market Size and Forecast, by Delivery Therapeutic Area (2023-2030) 6.6.6.2. Sweden Gene Therapy Market Size and Forecast, by Vector Type (2023-2030) 6.6.6.3. Sweden Gene Therapy Market Size and Forecast, by Therapeutic Area (2023-2030) 6.6.6.4. Sweden Gene Therapy Market Size and Forecast, by Route of Administration (2023-2030) 6.6.6.5. Sweden Gene Therapy Market Size and Forecast, by End User (2023-2030) 6.6.7. Austria 6.6.7.1. Austria Gene Therapy Market Size and Forecast, by Delivery Therapeutic Area (2023-2030) 6.6.7.2. Austria Gene Therapy Market Size and Forecast, by Vector Type (2023-2030) 6.6.7.3. Austria Gene Therapy Market Size and Forecast, by Therapeutic Area (2023-2030) 6.6.7.4. Austria Gene Therapy Market Size and Forecast, by Route of Administration (2023-2030) 6.6.7.5. Austria Gene Therapy Market Size and Forecast, by End User (2023-2030) 6.6.8. Rest of Europe 6.6.8.1. Rest of Europe Gene Therapy Market Size and Forecast, by Delivery Therapeutic Area (2023-2030) 6.6.8.2. Rest of Europe Gene Therapy Market Size and Forecast, by Vector Type (2023-2030) 6.6.8.3. Rest of Europe Gene Therapy Market Size and Forecast, by Therapeutic Area (2023-2030) 6.6.8.4. Rest of Europe Gene Therapy Market Size and Forecast, by Route of Administration (2023-2030) 6.6.8.5. Rest of Europe Gene Therapy Market Size and Forecast, by End User (2023-2030) 7. Asia Pacific Gene Therapy Market Size and Forecast by Segmentation (by Value USD Mn) (2023-2030) 7.1. Asia Pacific Gene Therapy Market Size and Forecast, by Delivery Therapeutic Area (2023-2030) 7.2. Asia Pacific Gene Therapy Market Size and Forecast, by Vector Type (2023-2030) 7.3. Asia Pacific Gene Therapy Market Size and Forecast, by Therapeutic Area (2023-2030) 7.4. Asia Pacific Gene Therapy Market Size and Forecast, by Route of Administration (2023-2030) 7.5. Asia Pacific Gene Therapy Market Size and Forecast, by End User (2023-2030) 7.6. Asia Pacific Gene Therapy Market Size and Forecast, by Country (2023-2030) 7.6.1. China 7.6.1.1. China Gene Therapy Market Size and Forecast, by Delivery Therapeutic Area (2023-2030) 7.6.1.2. China Gene Therapy Market Size and Forecast, by Vector Type (2023-2030) 7.6.1.3. China Gene Therapy Market Size and Forecast, by Therapeutic Area (2023-2030) 7.6.1.4. China Gene Therapy Market Size and Forecast, by Route of Administration (2023-2030) 7.6.1.5. China Gene Therapy Market Size and Forecast, by End User (2023-2030) 7.6.2. S Korea 7.6.2.1. S Korea Gene Therapy Market Size and Forecast, by Delivery Therapeutic Area (2023-2030) 7.6.2.2. S Korea Gene Therapy Market Size and Forecast, by Vector Type (2023-2030) 7.6.2.3. S Korea Gene Therapy Market Size and Forecast, by Therapeutic Area (2023-2030) 7.6.2.4. S Korea Gene Therapy Market Size and Forecast, by Route of Administration (2023-2030) 7.6.2.5. S Korea Gene Therapy Market Size and Forecast, by End User (2023-2030) 7.6.3. Japan 7.6.3.1. Japan Gene Therapy Market Size and Forecast, by Delivery Therapeutic Area (2023-2030) 7.6.3.2. Japan Gene Therapy Market Size and Forecast, by Vector Type (2023-2030) 7.6.3.3. Japan Gene Therapy Market Size and Forecast, by Therapeutic Area (2023-2030) 7.6.3.4. Japan Gene Therapy Market Size and Forecast, by Route of Administration (2023-2030) 7.6.3.5. Japan Gene Therapy Market Size and Forecast, by End User (2023-2030) 7.6.4. India 7.6.4.1. India Gene Therapy Market Size and Forecast, by Delivery Therapeutic Area (2023-2030) 7.6.4.2. India Gene Therapy Market Size and Forecast, by Vector Type (2023-2030) 7.6.4.3. India Gene Therapy Market Size and Forecast, by Therapeutic Area (2023-2030) 7.6.4.4. India Gene Therapy Market Size and Forecast, by Route of Administration (2023-2030) 7.6.4.5. India Gene Therapy Market Size and Forecast, by End User (2023-2030) 7.6.5. Australia 7.6.5.1. Australia Gene Therapy Market Size and Forecast, by Delivery Therapeutic Area (2023-2030) 7.6.5.2. Australia Gene Therapy Market Size and Forecast, by Vector Type (2023-2030) 7.6.5.3. Australia Gene Therapy Market Size and Forecast, by Therapeutic Area (2023-2030) 7.6.5.4. Australia Gene Therapy Market Size and Forecast, by Route of Administration (2023-2030) 7.6.5.5. Australia Gene Therapy Market Size and Forecast, by End User (2023-2030) 7.6.6. ASEAN 7.6.6.1. ASEAN Gene Therapy Market Size and Forecast, by Delivery Therapeutic Area (2023-2030) 7.6.6.2. ASEAN Gene Therapy Market Size and Forecast, by Vector Type (2023-2030) 7.6.6.3. ASEAN Gene Therapy Market Size and Forecast, by Therapeutic Area (2023-2030) 7.6.6.4. ASEAN Gene Therapy Market Size and Forecast, by Route of Administration (2023-2030) 7.6.6.5. ASEAN Gene Therapy Market Size and Forecast, by End User (2023-2030) 7.6.7. Rest of Asia Pacific 7.6.7.1. Rest of Asia Pacific Gene Therapy Market Size and Forecast, by Delivery Therapeutic Area (2023-2030) 7.6.7.2. Rest of Asia Pacific Gene Therapy Market Size and Forecast, by Vector Type (2023-2030) 7.6.7.3. Rest of Asia Pacific Gene Therapy Market Size and Forecast, by Therapeutic Area (2023-2030) 7.6.7.4. Rest of Asia Pacific Gene Therapy Market Size and Forecast, by Route of Administration (2023-2030) 7.6.7.5. Rest of Asia Pacific Gene Therapy Market Size and Forecast, by End User (2023-2030) 8. Middle East and Africa Gene Therapy Market Size and Forecast by Segmentation (by Value in USD Million) (2023-2030) 8.1. Middle East and Africa Gene Therapy Market Size and Forecast, by Delivery Therapeutic Area (2023-2030) 8.2. Middle East and Africa Gene Therapy Market Size and Forecast, by Vector Type (2023-2030) 8.3. Middle East and Africa Gene Therapy Market Size and Forecast, by Therapeutic Area (2023-2030) 8.4. Middle East and Africa Gene Therapy Market Size and Forecast, by Route of Administration (2023-2030) 8.5. Middle East and Africa Gene Therapy Market Size and Forecast, by End User (2023-2030) 8.6. Middle East and Africa Gene Therapy Market Size and Forecast, by Country (2023-2030) 8.6.1. South Africa 8.6.1.1. South Africa Gene Therapy Market Size and Forecast, by Delivery Therapeutic Area (2023-2030) 8.6.1.2. South Africa Gene Therapy Market Size and Forecast, by Vector Type (2023-2030) 8.6.1.3. South Africa Gene Therapy Market Size and Forecast, by Therapeutic Area (2023-2030) 8.6.1.4. South Africa Gene Therapy Market Size and Forecast, by Route of Administration (2023-2030) 8.6.1.5. South Africa Gene Therapy Market Size and Forecast, by End User (2023-2030) 8.6.2. GCC 8.6.2.1. GCC Gene Therapy Market Size and Forecast, by Delivery Therapeutic Area (2023-2030) 8.6.2.2. GCC Gene Therapy Market Size and Forecast, by Vector Type (2023-2030) 8.6.2.3. GCC Gene Therapy Market Size and Forecast, by Therapeutic Area (2023-2030) 8.6.2.4. GCC Gene Therapy Market Size and Forecast, by Route of Administration (2023-2030) 8.6.2.5. GCC Gene Therapy Market Size and Forecast, by End User (2023-2030) 8.6.3. Nigeria 8.6.3.1. Nigeria Gene Therapy Market Size and Forecast, by Delivery Therapeutic Area (2023-2030) 8.6.3.2. Nigeria Gene Therapy Market Size and Forecast, by Vector Type (2023-2030) 8.6.3.3. Nigeria Gene Therapy Market Size and Forecast, by Therapeutic Area (2023-2030) 8.6.3.4. Nigeria Gene Therapy Market Size and Forecast, by Route of Administration (2023-2030) 8.6.3.5. Nigeria Gene Therapy Market Size and Forecast, by End User (2023-2030) 8.6.4. Rest of ME&A 8.6.4.1. Rest of ME&A Gene Therapy Market Size and Forecast, by Delivery Therapeutic Area (2023-2030) 8.6.4.2. Rest of ME&A Gene Therapy Market Size and Forecast, by Vector Type (2023-2030) 8.6.4.3. Rest of ME&A Gene Therapy Market Size and Forecast, by Therapeutic Area (2023-2030) 8.6.4.4. Rest of ME&A Gene Therapy Market Size and Forecast, by Route of Administration (2023-2030) 8.6.4.5. Rest of ME&A Gene Therapy Market Size and Forecast, by End User (2023-2030) 9. South America Gene Therapy Market Size and Forecast by Segmentation (by Value USD Mn) (2023-2030) 9.1. South America Gene Therapy Market Size and Forecast, by Delivery Therapeutic Area (2023-2030) 9.2. South America Gene Therapy Market Size and Forecast, by Vector Type (2023-2030) 9.3. South America Gene Therapy Market Size and Forecast, by Therapeutic Area (2023-2030) 9.4. South America Gene Therapy Market Size and Forecast, by Route of Administration (2023-2030) 9.5. South America Gene Therapy Market Size and Forecast, by End User (2023-2030) 9.6. South America Gene Therapy Market Size and Forecast, by Country (2023-2030) 9.6.1. Brazil 9.6.1.1. Brazil Gene Therapy Market Size and Forecast, by Delivery Therapeutic Area (2023-2030) 9.6.1.2. Brazil Gene Therapy Market Size and Forecast, by Vector Type (2023-2030) 9.6.1.3. Brazil Gene Therapy Market Size and Forecast, by Therapeutic Area (2023-2030) 9.6.1.4. Brazil Gene Therapy Market Size and Forecast, by Route of Administration (2023-2030) 9.6.1.5. Brazil Gene Therapy Market Size and Forecast, by End User (2023-2030) 9.6.2. Argentina 9.6.2.1. Argentina Gene Therapy Market Size and Forecast, by Delivery Therapeutic Area (2023-2030) 9.6.2.2. Argentina Gene Therapy Market Size and Forecast, by Vector Type (2023-2030) 9.6.2.3. Argentina Gene Therapy Market Size and Forecast, by Therapeutic Area (2023-2030) 9.6.2.4. Argentina Gene Therapy Market Size and Forecast, by Route of Administration (2023-2030) 9.6.2.5. Argentina Gene Therapy Market Size and Forecast, by End User (2023-2030) 9.6.3. Rest Of South America 9.6.3.1. Rest Of South America Gene Therapy Market Size and Forecast, by Delivery Therapeutic Area (2023-2030) 9.6.3.2. Rest Of South America Gene Therapy Market Size and Forecast, by Vector Type (2023-2030) 9.6.3.3. Rest Of South America Gene Therapy Market Size and Forecast, by Therapeutic Area (2023-2030) 9.6.3.4. Rest Of South America Gene Therapy Market Size and Forecast, by Route of Administration (2023-2030) 9.6.3.5. Rest Of South America Gene Therapy Market Size and Forecast, by End User (2023-2030) 10. Company Profile: Key Players 10.1. Organogenesis 10.1.1. Company Overview 10.1.2. Business Portfolio 10.1.3. Financial Overview 10.1.4. SWOT Analysis (Technological strengths and weaknesses) 10.1.5. Strategic Analysis (Recent strategic moves) 10.1.6. Recent Developments 10.2. JCR Pharmaceuticals 10.3. Japan Tissue Engineering 10.4. AVITA Medical 10.5. CHIESI Farmaceutici 10.6. Stempeutics Research 10.7. Biosolution 10.8. MolMed 10.9. APAC Biotech 10.10. Gilead Sciences 10.11. Medipost 10.12. JW CreaGene 10.13. Vericel 10.14. Takeda Pharmaceutical Company 10.15. Novartis AG 10.16. Osiris Therapeutics 10.17. AnGes 10.18. Tego Sciences 10.19. Dendreon 10.20. CollPlant 11. Key Findings 12. Analyst Recommendations 13. Gene Therapy Market: Research Therapeutic Areaology
